Tag: OVAS

Finance

Stocks in Focus: API Technologies (NASDAQ:ATNY), Intercept Pharmaceuticals (NASDAQ:ICPT), OvaScience (NASDAQ:OVAS), Charles & Colvard Ltd. (NASDAQ:CTHR)

API Technologies Corp. (NASDAQ:ATNY), a leading provider of high performance RF/microwave, power, and security solutions for critical and high-reliability applications, announced today the launch of configurable frequency synthesizers (Models LCFS-X), the newest addition to the Company’s line of standard RF / microwave products. API Technologies Corp. (NASDAQ:ATNY) belongs to Technology sector. Its net profit margin is -7.90% and weekly performance is 0.00%. On last trading … Continue reading Stocks in Focus: API Technologies (NASDAQ:ATNY), Intercept Pharmaceuticals (NASDAQ:ICPT), OvaScience (NASDAQ:OVAS), Charles & Colvard Ltd. (NASDAQ:CTHR)

Jayne Crisman
Finance

Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and finished the day at $8.47. Traded volume was 69,618.00million shares … Continue reading Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Jason Knox
Finance

Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

ArQule Inc. (NASDAQ:ARQL) announced that the Company will present at the Needham 13th Annual Healthcare Conference. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website http://www.arqule.com. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.92% in last session and finished the day at $1.66. Traded volume was 530,559.00million shares in the last session and the average volume … Continue reading Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

Colin Pettis
Finance

Today’s Stocks : Acasti Pharma Inc. (NASDAQ:ACST), OvaScience, Inc. (NASDAQ:OVAS), Jack Henry & Associates Inc. (NASDAQ:JKHY), InvenSense, Inc. (NYSE:INVN), Facebook Inc (NASDAQ:FB)

On Sep 30, Acasti Pharma Inc. (NASDAQ:ACST), announces top-line results for its pharmacokinetic (PK) trial evaluating the bioavailability and safety of CaPre® on healthy individuals taking single and multiple daily oral doses of the Corporation’s new investigational drug candidate composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders. Acasti Pharma Inc. (NASDAQ:ACST) belongs to Healthcare sector. … Continue reading Today’s Stocks : Acasti Pharma Inc. (NASDAQ:ACST), OvaScience, Inc. (NASDAQ:OVAS), Jack Henry & Associates Inc. (NASDAQ:JKHY), InvenSense, Inc. (NYSE:INVN), Facebook Inc (NASDAQ:FB)

Mark Doerr
Finance

Traders Are Watching : Twenty-First Century Fox (NASDAQ:FOXA), Cliffs Natural Resources (NYSE:CLF), EMCORE (NASDAQ:EMKR), Chimera Investment Corporation (NYSE:CIM), OvaScience (NASDAQ:OVAS)

Twenty-First Century Fox, Inc. (NASDAQ:FOXA) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a report released on Tuesday. The firm currently has a $35.30 price objective on the stock. Zacks‘s price target suggests a potential upside of 2.50% from the stock’s previous close. Twenty-First Century Fox, Inc. (NASDAQ:FOXA) belongs to Services sector. Its net profit margin is 14.20% and weekly … Continue reading Traders Are Watching : Twenty-First Century Fox (NASDAQ:FOXA), Cliffs Natural Resources (NYSE:CLF), EMCORE (NASDAQ:EMKR), Chimera Investment Corporation (NYSE:CIM), OvaScience (NASDAQ:OVAS)

John Meady